Translational Pharmacological Research


Deferasirox intervention to prevent iron-related disorders Excess tissue iron content due to iron overload or accumulation is estimated to affect up to one hundred million worldwide and is often seen in individuals with hereditary hemochromatosis and in those who require frequent blood transfusions, such as individuals afflicted with thalassemia, sickle cell disease, and myelodysplastic syndrome. It is also thought that aging in rats and humans is associated with increases in iron accumulation. The accumulation of iron is toxic and can lead to heart failure which is the major cause of death following protracted iron overload. Although the causes of cardiomyopathy following iron overload are not fully understood, it has been suggested that excess tissue iron is associated with increases in myocardial oxidative stress, apoptosis and the development of fibrosis. We investigate whether how Deferasirox, an oral iron chelator, can attenuate iron overload-induced tissue damage, especially in the aged or iron-overloaded hearts.